Success of repeat detrusor injections of botulinum A toxin in patients with severe neurogenic detrusor overactivity and incontinence

被引:187
作者
Grosse, J [1 ]
Kramer, G [1 ]
Stöhrer, M [1 ]
机构
[1] Berufsgenossenschaft Unfallklin Murnau, Dept Urol, Murnau, Germany
关键词
botulinum; detrusor injections; neurogenic detrusor overactivity; neurogenic urinary incontinence; spinal cord injury; aseptic intermittent catheterisation; botulinum resistance;
D O I
10.1016/j.eururo.2004.11.009
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives: Detrusor injections with botulinum toxin type A are an effective treatment for neurogenic detrusor overactivity, lasting for 9-12 months. When the patients develop botulinum resistance, subsequent injections might be less effective. Repeat injections in patients with severe neurogenic detrusor overactivity and incontinence were studied. Methods: Patients received Botox((R)) (300 UI) or Dyspor((R))) (750 UI) injections. Clinical variables: satisfaction, anticholinergics use, mean and maximum bladder capacity, continence volume. Cystometric parameters: compliance, cystometric capacity, reflex volume. Statistics: Anova, chi(2)-tests; t-tests and paired t-tests (p = 0.05). Results: Forty-three men and 23 women (mean age 38.3 years; mean duration of lesion 9.2 years) were included. The interval between subsequent injections (on average 9-11 months) did not change significantly (p = 0.5594). The satisfaction was high and anticholinergics use decreased substantially (p = 0.0000). Significant improvements were found in clinical parameters and in cystometric capacity, for compliance only at the second treatment. The incidence of reflex contractions was significantly reduced. Four patients had transient adverse events after Dysporto. Conclusions: Repeat injections with botulinum toxin type A are as effective as the first one. The cause for repeat treatment is relapse of overactive bladder symptoms. (c) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:653 / 659
页数:7
相关论文
共 42 条
[1]  
Abrams P, 2002, NEUROUROL URODYNAM, V21, P167, DOI 10.1002/nau.10052
[2]   SECRETS OF SECRETION REVEALED [J].
BARINAGA, M .
SCIENCE, 1993, 260 (5107) :487-489
[3]   ABSENCE OF ANTIBODY-PRODUCTION IN PATIENTS TREATED WITH BOTULINUM-A TOXIN [J].
BIGLAN, AW ;
GONNERING, R ;
LOCKHART, LB ;
RABIN, B ;
FUERSTE, FH .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1986, 101 (02) :232-235
[4]   Obstructive uropathy in the male [J].
Blaivas, JG .
UROLOGIC CLINICS OF NORTH AMERICA, 1996, 23 (03) :373-&
[5]   Botulinum toxin therapy, immunologic resistance, and problems with available materials [J].
Borodic, G ;
Johnson, E ;
Goodnough, M ;
Schantz, E .
NEUROLOGY, 1996, 46 (01) :26-29
[6]   BOTULINUM A TOXIN FOR THE TREATMENT OF SPASMODIC TORTICOLLIS - DYSPHAGIA AND REGIONAL TOXIN SPREAD [J].
BORODIC, GE ;
JOSEPH, M ;
FAY, L ;
COZZOLINO, D ;
FERRANTE, RJ .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 1990, 12 (05) :392-399
[7]  
BRIN MF, 1993, J ROY SOC MED, V86, P494
[8]   THE FIRST 500 PATIENTS WITH SACRAL ANTERIOR ROOT STIMULATOR IMPLANTS - GENERAL DESCRIPTION [J].
BRINDLEY, GS .
PARAPLEGIA, 1994, 32 (12) :795-805
[9]   BLADDER AUTOAUGMENTATION - EARLY CLINICAL-EXPERIENCE [J].
CARTWRIGHT, PC ;
SNOW, BW .
JOURNAL OF UROLOGY, 1989, 142 (02) :505-508
[10]  
Consky E.S., 1994, THERAPY BOTULINUM TO, P211